Tratamento
If your GLP-1 medication seems to have plateaued, here's what physicians actually look at before making changes to your treatment plan.
Stopping GLP-1 therapy prematurely happens more often than it should. Here's what structured medical follow-up does differently—and why it matters for lasting results.
A practical guide explaining how Brazilian patients obtain GLP-1 prescriptions, the regulatory role of ANVISA, and what marketplace sales on platforms like Mercado Livre mean for treatment access.
Before purchasing a bundled Mounjaro offer, patients should understand the regulatory, financial, and safety risks involved. Here's what to look for.
Your weekly hunger pattern isn't in your head. Here's the science behind why GLP-1 appetite suppression fades before your next injection and what it actually means for your results.
The transition from loading dose to maintenance dose can bring real, noticeable changes. Here's what the science says about how your body typically responds during this phase.
Brazil's ANVISA has approved a new combined insulin-GLP-1 therapy for type 2 diabetes. Here's what this means for treatment options, patient access, and the broader diabetes care landscape in Brazil.
Understanding how GLP-1 dose titration works and why skipping steps can undermine your treatment progress and increase side effects.
Stay informed about recent ANVISA alerts regarding GLP-1 weight loss pens. Learn what the regulatory data reveals about safety concerns, counterfeit medications, and how patients can protect themselves when using these treatments.
Both semaglutide and tirzepatide are powerful GLP-1 medications, but they work differently. Learn how to match your clinical profile and treatment goals with the right option.
